

Corlanor - (5, 7.5 mg; Tablet, Oral)

| Generic Name | Ivabradine Hydrochloride | Innovator | Amgen |
|-----------------------|--|----------------------|---------------------|
| Dosage | 5, 7.5 mg; Tablet, Oral | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | More Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | Less Than 5 | Generic Launches | Less Than 5 |
| Indication | Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.